Loading...

UGI UGI CORP US FDA Inspections 8-K Filing

G CR

G

UGI CORP

(UGI)

2025 8-K

Financial Results Update

Credit Agreement Update

Receivables Agreement Update

Financial Statements

Debt-Equity Swaps

Debt-Equity Swaps

Debt Restructuring

Debt Restructuring

Financial Statements

Debt Securities

Credit Agreement Amendment

Financial Results

Note Redemption

Shareholder Meeting

Financial Results

Note Purchase Agreement

Credit Agreement Amendment

Accounting Firm Change

Receivables Agreement Update

Leadership Change

Credit Agreement

Director Appointments

Director Appointment

Departure of Directors or C...

Credit Agreement

Credit Agreement Amendment

Tender Offer Results

Agreement for ESG Targets

Issuance of Convertible Sen...

Departure of Directors or C...

Credit Agreement

Amendment to Credit Agreements

Resignation of Director

Departure of CEO

Annual Meeting of Shareholders

CEO Departure and Appointment

Note Purchase Agreement

Credit Agreement Amendment

Financial Results Announcement

Credit Agreement and Termin...

Amendment to Receivables Pu...

Departure of Directors

Amendment to Credit Agreement

Appointment of Director

Senior Notes Issued

Tender Offer Results

Offering Pricing

Private Offering and Tender...

Credit Agreement Amendments

Departure of Directors or C...

Amendments to Bylaws

Financial Results Announcement

External Links:

On May 28, 2025, UGI Corporation announced that its subsidiaries completed a tender offer for 5.875% Senior Notes due 2026, with approximately $553.3 million representing about 83.3% of the notes validly tendered by the expiration date of May 27, 2025.

AI Assistant

UGI CORP

2025

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.